| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Benzododecinium chloride acts as a cationic surfactant that disrupts the cell membrane of microorganisms. It interacts with the negatively charged phospholipid bilayer of the bacterial cell membrane, causing leakage of intracellular contents and cell lysis. It is effective against a wide range of Gram-positive and Gram-negative bacteria, as well as some fungi.
|
|---|---|
| ln Vitro |
In vitro, benzododecinium chloride exhibits potent antibacterial and antifungal activity. Its minimum inhibitory concentration (MIC) for susceptible bacterial strains is typically in the low microgram per milliliter range. It is effective against both planktonic bacteria and those in biofilms. Its activity is reduced in the presence of organic matter.
|
| ln Vivo |
In vivo, benzododecinium chloride is used as a topical antiseptic and disinfectant. It is used in solutions for skin disinfection, wound cleansing, and as a preservative in ophthalmic and nasal preparations. It is also used in some mouthwashes and throat lozenges. Its use is limited to topical applications due to its irritant properties.
|
| Enzyme Assay |
The in vitro antibacterial activity of benzododecinium chloride is assessed using standard broth dilution or agar dilution methods. The minimum inhibitory concentration (MIC) is determined by culturing bacteria in the presence of serial dilutions of the compound. The lowest concentration that inhibits visible bacterial growth is recorded as the MIC.
|
| Cell Assay |
In vitro cellular assays for benzododecinium chloride are not typically performed, as it is an antiseptic that acts on bacterial cell membranes. Its cytotoxicity can be assessed using mammalian cell lines to evaluate its safety for topical use. Cells are exposed to the compound, and cell viability is measured using MTT or LDH assays to determine the cytotoxic concentration (CC50).
|
| Animal Protocol |
In vivo animal experiments for benzododecinium chloride are not typical, as it is a topical antiseptic, not a drug. However, safety and irritation studies may be conducted on animal skin or mucous membranes to assess its irritancy and sensitization potential. These studies are required for its use in pharmaceutical and cosmetic products.
|
| ADME/Pharmacokinetics |
Benzododecinium chloride is not significantly absorbed through intact skin. When used topically, its systemic absorption is minimal. It is primarily eliminated through the skin and by washing. No significant pharmacokinetic studies are required for topical antiseptics, as systemic exposure is negligible.
|
| Toxicity/Toxicokinetics |
Benzododecinium chloride can cause local irritation and allergic reactions in some individuals. It is irritating to the eyes and mucous membranes. Prolonged use can cause skin dryness and dermatitis. It should not be ingested. It is generally safe for use in topical products at the concentrations employed.
|
| Additional Infomation |
Benzododecinium chloride is an organochlorine salt of Benzododecinium. It possesses antibacterial and disinfectant properties and can be used as a preservative in eye drop formulations. It can also be used as an antibacterial agent, disinfectant, antifouling agent, and surfactant. It is a quaternary ammonium salt and organochlorine salt containing Benzododecinium.
See also: ...View more... Benzododecinium chloride is a common preservative and antiseptic in pharmaceutical and cosmetic products. It is also used as a disinfectant in healthcare settings. It is a member of the benzalkonium chloride family, which are widely used quaternary ammonium compounds. It is not a drug but an excipient used in many over-the-counter and prescription products. |
| Molecular Formula |
C21H38CLN
|
|---|---|
| Molecular Weight |
339.9861
|
| Exact Mass |
339.269
|
| CAS # |
139-07-1
|
| Related CAS # |
10328-35-5 (Parent)
|
| PubChem CID |
8753
|
| Appearance |
White to light brown <42°C solid powder,>42°C liquid
|
| Melting Point |
~60 °C
|
| LogP |
3.187
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
23
|
| Complexity |
240
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].[N+](C([H])([H])[H])(C([H])([H])[H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
JBIROUFYLSSYDX-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C21H38N.ClH/c1-4-5-6-7-8-9-10-11-12-16-19-22(2,3)20-21-17-14-13-15-18-21;/h13-15,17-18H,4-12,16,19-20H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
benzyl-dodecyl-dimethylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~294.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9413 mL | 14.7063 mL | 29.4126 mL | |
| 5 mM | 0.5883 mL | 2.9413 mL | 5.8825 mL | |
| 10 mM | 0.2941 mL | 1.4706 mL | 2.9413 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
